Kunming Pharma Group 2025 Annual Report Interpretation: Non-GAAP Net Profit Plummets 74.45% and Financial Expenses Surge 209.20%

Core Profitability Indicators Analysis

Operating Revenue: Shrinking by Over 20%, Main Business Under Significant Pressure

During the reporting period, the company achieved an operating revenue of 6.575 billion yuan, down 21.74% year-over-year. In terms of business structure, oral dosage products in the pharmaceutical industrial sector saw a 37.36% YoY decline, significantly affected by fluctuations in retail terminal traffic and intensified industry competition; anti-malarial products revenue dropped 32.13%, mainly due to adjustments in international market demand. The pharmaceutical commercial sector’s revenue decreased by 10.52%, indicating an overall contraction in scale.

Net Profit: Halved, Non-Recurring Gains Support Bottom Line

Net profit attributable to shareholders of the listed company was 350 million yuan, a 46.00% decrease YoY. Net profit excluding non-recurring gains was only 107 million yuan, plunging 74.45% YoY, indicating a sharp decline in core profitability. Non-recurring gains and losses became an important support, totaling 243 million yuan for the year, including fair value changes of financial assets of 121 million yuan and government grants of 82 million yuan, accounting for over 69% of net profit.

Earnings Per Share: Shrinking in Tandem, Non-Recurring Items Show Significant Drop

Basic earnings per share were 0.46 yuan/share, down 46.51% YoY; adjusted (non-recurring) basic EPS was only 0.14 yuan/share, a 74.55% decline, consistent with the significant drop in net profit excluding non-recurring items, reflecting a notable decline in the quality of core business profits.

Cost Structure Deep Dive

Overall Expenses: Scale Shrinks, Structural Differentiation Evident

Total expenses for the year amounted to 2.233 billion yuan, down 12.17% YoY, but with notable structural differences. Financial expenses surged sharply, while selling, management, and R&D expenses experienced varying degrees of change.

Selling Expenses: Decline Alongside Revenue, Market Promotion Weakening

Selling expenses decreased by 23.25% YoY, mainly due to reduced marketing costs, from 1.713 billion yuan in 2024 to 1.224 billion yuan, a 28.54% drop, consistent with revenue contraction, reflecting reduced market investment.

Management Expenses: Slight Increase, Stable Scale

Management expenses increased marginally by 1.97%, maintaining overall stability. High proportions of fixed costs such as employee compensation and depreciation continue to exert pressure on expense control.

Financial Expenses: Sharp Rise, Interest Payments Doubling

Financial expenses surged by 209.20% YoY, mainly due to increased borrowings leading to higher interest costs. Total interest expenses for the year reached 506 million yuan, up 91.86%, while interest income was only 100 million yuan, down 22.18%, resulting in a significant increase in net interest expenditure.

R&D Expenses: Slight Decrease, Investment Structure Optimized

R&D expenses decreased slightly by 3.95%, with total R&D investment reaching 149.423 million yuan, including 46.875 million yuan capitalized, accounting for 31.37%, an improvement over the previous year, indicating increased capitalization of R&D costs.

R&D Personnel and Innovation Capacity Analysis

The company has 236 R&D staff, accounting for 4.65% of total employees. Among them, 79 hold master’s degrees or higher, representing 33.47%; undergraduates and above account for 88.56%, indicating a highly educated R&D team. Age-wise, 71.19% are between 30-50 years old, forming a core middle-aged and young R&D echelon with strong innovation vitality.

During the reporting period, the company’s innovative drug projects advanced steadily: a Class 1 new chemical drug for solid tumors (079) is in Phase I clinical trials; a Class 1 new chemical drug for non-alcoholic fatty liver disease (111) entered Phase I; a natural medicine Class 1 new drug (020) progressed to Phase II. The generic drug project achieved breakthroughs, with three Class 3 chemical drug projects (150) approved, including a treatment for hyperphosphatemia in adult chronic kidney disease patients, enriching the company’s product pipeline in chronic disease areas.

Cash Flow Analysis

Overall Cash Flow: Turned Negative, Funding Pressure Intensifies

Net cash and cash equivalents for the year were -1.003 billion yuan, turning from positive to negative, indicating increased funding pressure. Operating, investing, and financing cash flows show a pattern of “one positive, two negative,” with outflows concentrated in investing and financing activities.

Operating Cash Flow: Sharp Decline, Reduced Cash Generation

Net cash flow from operating activities was 289 million yuan, down 64.21% YoY. This was mainly due to decreased revenue, with cash received from sales of goods and services dropping from 8.176 billion yuan to 7.160 billion yuan, a 12.17% decline; cash paid for purchases and services also decreased but less than inflows, leading to a significant reduction in net operating cash flow.

Investing Cash Flow: Large Outflows, Expansion of Investment Scale

Net cash flow from investing activities was -637 million yuan, shifting from net inflow to large net outflow, mainly due to increased investment in financial products. Payments for investments totaled 5.892 billion yuan, nearly doubling (+97.73%), with trading financial assets reaching 1.109 billion yuan, up 135.32% from the beginning of the year.

Financing Cash Flow: Continued Outflows, Debt Structure Adjustment

Net cash flow from financing activities was -655 million yuan, with an increased scale of outflows mainly due to payments for acquisitions and debt repayments. Borrowings received totaled 1.74 billion yuan, up 123.87%, but debt repayments and acquisition payments (125 million yuan) led to a significant increase in cash outflows.

Risk Factors Warning

Policy and Market Risks: Dual Pressure from Medical Insurance Cost Control and Channel Reform

Deepening policies on medical insurance cost control, such as “Three Same” and “Four Same” policies, promote price convergence of drugs inside and outside hospitals, restrict prescription outside, and challenge traditional marketing models. The scope of centralized procurement with volume-based bidding has expanded, exerting long-term pressure on product profitability, with some products facing price reduction risks.

Supply Chain Risks: Raw Material Price Fluctuations and Supply Stability

Prices of Chinese medicinal materials are affected by macroeconomic factors and natural disasters, with ongoing volatility risks. New pharmacopoeia standards increase procurement costs and supply pressures, challenging raw material supply stability.

R&D Risks: Long Cycle and High Uncertainty

Drug R&D involves long cycles and significant investment, with uncertainties in technology, market, and policy. There is a risk that innovative drug projects may not meet expectations or fail, potentially adversely affecting future performance.

Executive Compensation

During the reporting period, the company’s key executives’ compensation was as follows:

• Chairman Yu Xiang received a pre-tax total of 0 yuan, paid by affiliated party China Resources Sanjiu;
• General Manager Zhong Jiang received 0 yuan pre-tax, paid by affiliated party;
• Executive Vice President Meng Li received 1.7703 million yuan pre-tax;
• CFO Sun Zhiqiang received 1.3761 million yuan pre-tax;
• Senior Vice President Liu Junfeng received 2.1499 million yuan pre-tax;
• Vice President Zhang Mengxun received 1.327 million yuan pre-tax;
• Vice President Gao Tong received 1.5744 million yuan pre-tax;
• Vice President Sun Cheng received 1.9867 million yuan pre-tax.

Overall, the company’s executive compensation is linked to performance. Amid significant performance declines, some executives’ pay has been adjusted, reflecting a performance-based compensation mechanism.

Click to view the original announcement>>

Disclaimer: Market risks exist; investment should be cautious. This article is automatically generated by an AI model based on third-party data and does not represent Sina Finance’s views. All information herein is for reference only and does not constitute personal investment advice. Please refer to official announcements for actual data. For questions, contact biz@staff.sina.com.cn.